The overall aim of the ARCHER project is to develop the first antimicrobial impregnated breakaway connection device that prevents central line associated blood stream infections in patients undergoing central venous catheter intravenous (IV) therapy, decreasing healthcare expenses, and reducing patient morbidity and suffering. AM-ReLink, can reduce the introduction of bacteria into the bloodstream and decrease the instances of accidental tube dislodgement that occur in up to 36% of the IV treatments. We aim to reach the human clinical trial testing phase 3 months after project end, commercial agreements within 22 months and market launch within 24 months.
The project consists of 3 key milestones: 1) a sharply defined plan of the prototype and of each component, with clear technical characteristics on the functioning of each subsystems; 2) mature and finalizing the AM-ReLink subcomponents to achieve the most adequate antimicrobial impregnation method (lead: Amicoat) and to develop a family of connectors impregnated with antimicrobial of different sizes (lead: Tada). As final outcome partners will reach the technical functionality necessary to subsequently converge into a single product and 3) transfer of lab-scale processes into manufacture of prototype that will undergo qualification ready for the regulatory documentation phase (lead: Tada).
The project is well aligned to the EUROSTARS programme, designed to support research intensive SMEs with early-stage high risk R&D-focused projects with a large potential market and a short route to market (< two years) which is a good characterisation of this project.
The ARCHER project unites a complemental consortium. The coordinating organisation is Tada Medical AB (SE), who will undertake the overall management. The consortium brings together all necessary expertise, covering the whole value chain to research, develop and demonstrate ARCHER on the international stage.